title: A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.
abstract: OBJECTIVE
  This clinical study was designed to evaluate the efficacy and safety of this therapy in the treatment of respiratory and urinary infections caused by ceftriaxone-resistant bacteria in comparison with the effect of cefoperazone/sulbactam on cefoperazone-resistant bacteria.
  
  
  METHODS
  A total of 285 patients aged from 18 to 65 years old, with a respiratory or urinary tract bacterial infection, were enrolled into this multicentre, open-label, controlled clinical study, and bacteria that were either ceftriaxone-resistant or cefoperazone-resistant were isolated from the patients, whose condition had not improved after three days of treatment with ceftriaxone or cefoperazone. To be selected for the study, bacterial cultures obtained from the patients had to be positive before enrolment, and all of the isolates were required to be β-lactamase-positive. Of these patients, 253 completed the trial, and 263 were enrolled into the intention-to-treat (ITT) analysis. All of the 285 patients were included in the safety analysis.
  
  
  RESULTS
  The cure and effective rates were 39.55% and 85.07% in the ceftriaxone/sulbactam group and 36.43% and 79.84% in the cefoperazone/sulbactam group; the bacterial eradication rates were 83.58% and 83.72%; and the adverse-event rates were 7.48% and 7.80%, respectively. There were no significant differences between the two groups (p > 0.05).
  
  
  CONCLUSIONS
  Ceftriaxone/sulbactam is as effective and well-tolerated as cefoperazone/sulbactam for the treatment of intermediate and severe bacterial infections caused by resistant strains.
authors: Xiaojuan
authors: X
authors: Xin
authors: Li
authors: L
authors: Jian
authors: Xiaoying
authors: X
authors: Xia
authors: Key Laboratory of Infectious and Parasitic Diseases in Chongqing, Department of Infectious Diseases, the First Affiliated Hospital of Chongqing Medical University, No, 1 Youyi Road, Yu Zhong District, Chongqing 400016, China. beijia7410@163.com.
authors: Bei
authors: B
authors: Jia
authors: Wenxiang
authors: W
authors: Huang
authors: Chongzhi
authors: C
authors: Li
authors: Changzheng
authors: C
authors: Wang
authors: Lixin
authors: L
authors: Zhou
authors: Xiuzhen
authors: X
authors: Sun
authors: Xinghuo
authors: X
authors: Tang
authors: Yijiang
authors: Y
authors: Huang
authors: Yunkui
authors: Y
authors: Zhu
authors: Weili
authors: W
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000009:adverse effects / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013407:Sulbactam / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy*; D055815:Young Adult; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D002438:Cefoperazone; D013407:Sulbactam